0001209191-22-054512.txt : 20221025 0001209191-22-054512.hdr.sgml : 20221025 20221025163547 ACCESSION NUMBER: 0001209191-22-054512 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221021 FILED AS OF DATE: 20221025 DATE AS OF CHANGE: 20221025 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rochlin Kate CENTRAL INDEX KEY: 0001898521 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39692 FILM NUMBER: 221329908 MAIL ADDRESS: STREET 1: IN8BIO, INC. STREET 2: EMPIRE STATE BUILDING, SUITE 5330 CITY: NEW YORK STATE: NY ZIP: 10118 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IN8BIO, INC. CENTRAL INDEX KEY: 0001740279 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 825462585 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: EMPIRE STATE BUILDING STREET 2: 350 5TH AVENUE, SUITE 5330 CITY: NEW YORK STATE: NY ZIP: 10118 BUSINESS PHONE: (646) 600-6438 MAIL ADDRESS: STREET 1: EMPIRE STATE BUILDING STREET 2: 350 5TH AVENUE, SUITE 5330 CITY: NEW YORK STATE: NY ZIP: 10118 FORMER COMPANY: FORMER CONFORMED NAME: Incysus Therapeutics, Inc. DATE OF NAME CHANGE: 20180510 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-10-21 0 0001740279 IN8BIO, INC. INAB 0001898521 Rochlin Kate C/O IN8BIO, INC. 350 5TH AVE. SUITE 5330 NEW YORK NY 10118 0 1 0 0 Chief Operating Officer Employee Stock Option (right to buy) 1.48 2022-10-21 4 A 0 60555 0.00 A 2032-10-21 Common Stock 60555 60555 D The option will vest in three equal annual installments commencing on October 21, 2024, subject to the Reporting Person continuing to provide service through each such date. /s/ Jason Minio, Attorney-in-Fact 2022-10-25